April 2, 2020
Peter A. Lio, MD
It's a "super-exciting" time in the world of atopic dermatitis because of a number of new developments happening very rapidly, shares Peter Lio, MD. Recent approvals and additional indications for treatments like dupilumab and crisaborole in pediatric populations have been welcome additions. And there are biologics—IL-13 and IL-31 inhibitors—and JAK inhibitors in the pipeline showing promise.